Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · N970003/S304

ALTRUA 2 (Models S701, S702, S722) ESSENTIO (Models L100, L101, L121) PROPONENT (Models L200, L201, L221) ACCOLADE (

Boston Scientific Corp · Decision date Dec 19, 2025

FDA DECISIONN970003/S304

What did the FDA approve?

FDA records N970003/S304 as a supplement to PMA null, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 19, 2025.

FDA approval order statement

approval for the Software Maintenance Release 6 (SMR6) package of software updates for the ACCOLADE family of pacemakers and CRT-Ps
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Dec 19, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
N970003/S304
Regulatory pathway
PMA supplement
Product code
LWP
Decision code
APPR
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. N970003/S304 received

    Application receipt date recorded by FDA.

  2. N970003/S304 · FDA decision

    Real-Time Process

Related devices and submissions

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
4100 Hamline Ave. N, St Paul, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records